Simris Alg AB (publ) (SIMRIS-B) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Simris Alg AB (publ) (SIMRIS-B) has a cash flow conversion efficiency ratio of -0.723x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-3.97 Million ≈ $-426.91K USD) by net assets (Skr5.49 Million ≈ $590.38K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Simris Alg AB (publ) balance sheet independence to measure how much of total assets are equity-financed.
Simris Alg AB (publ) - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Simris Alg AB (publ)'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Simris Alg AB (publ) total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
Simris Alg AB (publ) Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Simris Alg AB (publ) ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SenzaGen AB
ST:SENZA
|
-0.052x |
|
Climeon AB (publ)
ST:CLIME-B
|
-0.070x |
|
Leeuwin Metals Ltd
AU:LM1
|
-0.042x |
|
Securemetric Berhad
KLSE:0203
|
0.083x |
|
Firefly Neuroscience, Inc.
NASDAQ:AIFF
|
-0.154x |
|
Wanted Lab Inc.
KQ:376980
|
0.039x |
|
EG Corporation
KQ:037370
|
-0.059x |
|
Curis Inc
NASDAQ:CRIS
|
-0.708x |
Annual Cash Flow Conversion Efficiency for Simris Alg AB (publ) (2014–2025)
The table below shows the annual cash flow conversion efficiency of Simris Alg AB (publ) from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see SIMRIS-B company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr-470.00K ≈ $-50.58K |
Skr-16.05 Million ≈ $-1.73 Million |
34.138x | +1168.91% |
| 2024-12-31 | Skr5.64 Million ≈ $607.06K |
Skr-18.02 Million ≈ $-1.94 Million |
-3.194x | -125.03% |
| 2023-12-31 | Skr25.61 Million ≈ $2.76 Million |
Skr-36.35 Million ≈ $-3.91 Million |
-1.419x | -79.74% |
| 2022-12-31 | Skr23.03 Million ≈ $2.48 Million |
Skr-18.19 Million ≈ $-1.96 Million |
-0.790x | +20.67% |
| 2021-12-31 | Skr18.22 Million ≈ $1.96 Million |
Skr-18.14 Million ≈ $-1.95 Million |
-0.995x | -142.26% |
| 2020-12-31 | Skr47.42 Million ≈ $5.10 Million |
Skr-19.48 Million ≈ $-2.10 Million |
-0.411x | +16.96% |
| 2019-12-31 | Skr35.00 Million ≈ $3.77 Million |
Skr-17.32 Million ≈ $-1.86 Million |
-0.495x | +11.61% |
| 2018-12-31 | Skr39.78 Million ≈ $4.28 Million |
Skr-22.27 Million ≈ $-2.40 Million |
-0.560x | -1.15% |
| 2017-12-31 | Skr42.68 Million ≈ $4.59 Million |
Skr-23.62 Million ≈ $-2.54 Million |
-0.553x | -93.91% |
| 2016-12-31 | Skr65.32 Million ≈ $7.03 Million |
Skr-18.64 Million ≈ $-2.01 Million |
-0.285x | -32.17% |
| 2015-12-31 | Skr38.68 Million ≈ $4.16 Million |
Skr-8.35 Million ≈ $-898.81K |
-0.216x | +75.83% |
| 2014-12-31 | Skr9.78 Million ≈ $1.05 Million |
Skr-8.73 Million ≈ $-939.92K |
-0.893x | -- |
About Simris Alg AB (publ)
Simris Group AB (PUBL), a biotechnology company, develops antibody-drug conjugate (ADC) payloads in Sweden and internationally. The company develops, manufactures, and sells bioactive substances from cultured microalgae and cyanobacteria. It also offers cosmetics and skincare products; biopharmaceuticals; and dietary supplements. The company was incorporated in 2011 and is headquartered in Hammen… Read more